Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.
The Motley Fool October 18, 2006 Brian Lawler	Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool October 30, 2007 Billy Fisher	Is Forest Labs' Nebivolol Ready for Prime Time? Shareholders of the pharmaceutical company have been looking for a way to boost their floundering stock. The FDA's likely approval of hypertension drug Nebivolol may be the answer.
The Motley Fool February 22, 2011 Brian Orelli	Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
The Motley Fool May 1, 2006 Stephen D. Simpson	Short-Term Fears Chip Into Forest Investors may be getting a second chance at unconventional Forest Labs. With the stock having pulled back, it's now very close to a tantalizing price.
The Motley Fool January 16, 2008 Brian Orelli	Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again.
The Motley Fool August 23, 2010 Brian Orelli	No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week.
The Motley Fool December 24, 2009 Brian Orelli	Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety.
The Motley Fool April 16, 2008 Brian Orelli	Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development.
The Motley Fool September 30, 2005 Stephen D. Simpson	Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note.
The Motley Fool April 19, 2005 Stephen D. Simpson	Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look.
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool October 18, 2005 Stephen D. Simpson	Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note.
The Motley Fool November 29, 2005 Stephen D. Simpson	Forest Seeds Future Growth A new deal with long-term benefits signals that the pharmaceutical remains credible. Patient investors may yet find this stock worth some due diligence.
The Motley Fool November 30, 2009 Brian Orelli	Anxious No Longer Eli Lilly adds another approval onto Cymbalta.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	A Clearing in the Forest? Despite so-so results, the biotech stock's slide may finally be over.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool March 11, 2010 Jim Mueller	Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices?
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool November 16, 2010 Luke Timmerman	Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool April 12, 2004 Brian Gorman	Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors.
The Motley Fool October 22, 2009 Robert Steyer	Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
The Motley Fool January 17, 2006 Stephen D. Simpson	Forest Labs: Is Different Better? Forest isn't your typical pharmaceutical company, and that's both its boon and its bane for investors.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool April 8, 2011 Brian Orelli	A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals.